Amylyx Pharmaceuticals Investor Lawsuit: Overstated Drug Potential?

Lawsuit Filed Against Amylyx Pharmaceuticals for Securities Violations

New York – Bernstein Liebhard LLP, a leading law firm specializing in securities litigation, has filed a class action lawsuit against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of investors who purchased the company’s securities between November 11, 2022, and November 8, 2023. The lawsuit, lodged in the United States District Court for the Southern District of New York, alleges that the biotechnology firm, which focuses on treatments for neurodegenerative diseases, violated the Securities Exchange Act of 1934.